ClinicaliQ Trial Snapshot
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) — Recruiting • Phase III • Oncology • NCT07549412.
- What is being tested: Precemtabart tocentecan (Precem-TcT), administered with or without bevacizumab, is being compared against the standard treatment of trifluridine/tipiracil plus bevacizumab in heavily pre-treated metastatic colorectal cancer, with overall survival as the primary endpoint.
- Patient eligibility overview: The trial targets patients with metastatic colorectal cancer who have exhausted standard first and second-line chemotherapy regimens (irinotecan, oxaliplatin, fluoropyrimidine, and bevacizumab), representing a treatment-refractory population with limited options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Eligibility Snapshot
- : * Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setting. * Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting * Eastern Cooperative Oncology Group (ECOG) performance status less than equal to 1 * Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations * Other protocol defined inclusion criteria may apply
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.